Another Kid on the Block: Long-acting FGF21 Analogue to Treat Dyslipidemia and Fatty Liver

J Clin Endocrinol Metab. 2022 Jan 1;107(1):e417-e419. doi: 10.1210/clinem/dgab686.

Authors

Ranyao Yang^{1

2}, Aimin Xu^{1

2

3}, Alexei Kharitonenkov⁴

Affiliations

¹ State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kong, Pokfulam, Hong Kong 999077, China.
² Department of Medicine, The University of Hong Kong, Pokfulam, Hong Kong 999077, China.
³ Department of Pharmacology & Pharmacy, The University of Hong Kong, Pokfulam, Hong Kong 999077, China.
⁴ AK Biotechnologies LLC, West Palm Beach, Florida 33401, USA.

No abstract available

Keywords: fibroblast growth factor 21 (FGF21); hypertriglyceridemia; metabolism; nonalcoholic fatty liver diseases (NAFLD); obesity.

Publication types

Editorial
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Dyslipidemias* / drug therapy
Fatty Liver* / drug therapy
Fibroblast Growth Factors
Humans

Substances

fibroblast growth factor 21
Fibroblast Growth Factors